Share price · NBTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NBTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Oct 2026+13.0%
Nothing announced by NBTX that day or the session before.
- 20 Oct 2026+14.5%
- 1 Oct 2026-10.5%
- 24 Aug 2026-8.9%
Nothing announced by NBTX that day or the session before.
- 17 Aug 2026+9.8%
Nothing announced by NBTX that day or the session before.
- 11 May 2026+17.7%
Nothing announced by NBTX that day or the session before.
- 6 May 2026+20.4%
- Day beforeNanobiotix: 6-K filing
- 4 May 2026-11.3%
- 11 Mar 2026-14.0%
Nothing announced by NBTX that day or the session before.
- 9 Mar 2026+18.1%
Nothing announced by NBTX that day or the session before.
Share of unusual movement by asset
For each asset, the share of NBTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
NBTXR3events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 29% |
| Sessions with no dated event | — | 71% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Hafnium-oxide nanoparticle radioenhancerOther | Non-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $37M | $26M | $62M | $6.8M-$38M operating cash flow | report ↗ |
Insider transactions
This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 15 reporting institutions held 5.7M shares ($175.9M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | JOHNSON & JOHNSON | 5,623,816 | $173.6M |
| 2 | MORGAN STANLEY | 36,274 | $1.1M |
| 3 | Optiver Holding B.V. | 13,501 | $417K |
| 4 | MARSHALL WACE, LLP | 9,239 | $285K |
| 5 | UBS Group AG | 5,557 | $172K |
| 6 | BNP PARIBAS FINANCIAL MARKETS | 3,559 | $110K |
| 7 | RHUMBLINE ADVISERS | 2,281 | $70K |
| 8 | ROYAL BANK OF CANADA | 1,825 | $56K |
| 9 | GAMMA Investing LLC | 828 | $26K |
| 10 | EverSource Wealth Advisors, LLC | 514 | $16K |
| 11 | OSAIC HOLDINGS, INC. | 500 | $15K |
| 12 | WELLS FARGO & COMPANY/MN | 200 | $6K |
| 13 | NATIONAL BANK OF CANADA /FI/ | 13 | $394 |
| 14 | Tower Research Capital LLC (TRC) | 1 | $31 |
| 15 | CITIGROUP INC | 1 | $31 |